WS
APLT

Wedbush Securities’s Applied Therapeutics APLT Stock Holding History

Wedbush Securities’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,000
Closed -$327K – 959
2020
Q1 		$327K Buy
+10,000
New +$404K 0.04% 498

Other funds holding APLT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Wedbush Securities's APLT Position: Q2 2020 in Review

Wedbush Securities sold out of Applied Therapeutics (APLT) in Q2 2020, closing a stake of 10,000 shares — an estimated $327K sold.

Wedbush Securities first reported a position in APLT in Q1 2020 and held it in 1 quarter. The position peaked at $327K in Q1 2020. 73 funds tracked by Wall St. Rank hold APLT as of Q2 2020.

  • Wedbush Securities reported no remaining Applied Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Wedbush Securities sold 10,000 Applied Therapeutics shares in Q2 2020, an estimated $327K.
  • Wedbush Securities first reported a position in Applied Therapeutics in Q1 2020 and held it in 1 quarter.
  • Wedbush Securities's Applied Therapeutics position peaked at $327K in Q1 2020.
  • 73 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2020.

Based on Wedbush Securities's 13F filing for Q2 2020, filed 16 Jul 2020.